JSC Grindeks is an internationally operating Latvian pharmaceutical company with headquarters in Riga, Latvia. Its portfolio consists of original products, generics, and active pharmaceutical ingredients. It mostly focuses on cardiovascular, central nervous system, anti-cancer and diabetes medicines.

Revenue(RF), mln.USD
Staff(RF), 2021
Assets(RF), mln.USD
Taxes(RF), mln.USD
The Company Statement
August 28, 2023

The pharma giant Grindeks exporting to Belarus, whereas its subsidiary Kalceks exports to Russia. Grindeks' turnover in 2022 was EUR 258 million, of which EUR 70.6 in Russia.

All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.